Alkermes plc (NASDAQ: ALKS) is 7.46% higher on its value in year-to-date trading and has touched a low of $22.90 and a high of $32.88 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ALKS stock was last observed hovering at around $29.65 in the last trading session, with the day’s gains setting it 0.16%.
Currently trading at $29.81, the stock is -1.44% and 3.30% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.77 million and changing 0.54% at the moment leaves the stock 11.72% off its SMA200. ALKS registered 6.96% gain for a year compared to 6-month gain of 22.73%. The firm has a 50-day simple moving average (SMA 50) of $28.8204 and a 200-day simple moving average (SMA200) of $26.676.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 1.53% loss in the last 1 month and extending the period to 3 months gives it a 9.72%, and is -0.86% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.23% over the week and 2.69% over the month.
Alkermes plc (ALKS) has around 2100 employees, a market worth around $4.82B and $1.51B in sales. Current P/E ratio is 15.18 and Fwd P/E is 16.79. Profit margin for the company is 22.15%. Distance from 52-week low is 30.17% and -9.34% from its 52-week high. The company has generated returns on investments over the last 12 months (20.22%).
with sales reaching $380.74M over the same period.The EPS is expected to grow by 82.21% this year, but quarterly earnings will post -9.38% year-over-year. Quarterly sales are estimated to grow 0.87% in year-over-year returns.
476.0 institutions hold shares in Alkermes plc (ALKS), with institutional investors hold 115.31% of the company’s shares. The shares outstanding are 161.78M, and float is at 158.79M with Short Float at 7.87%. Institutions hold 113.82% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 29.11 million shares valued at $701.49 million. The investor’s holdings represent 17.3276 of the ALKS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 20.0 million shares valued at $482.0 million to account for 11.9058 of the shares outstanding. The other top investors are WELLINGTON MANAGEMENT GROUP LLP which holds 14.35 million shares representing 8.5453 and valued at over $345.95 million, while PRICE T ROWE ASSOCIATES INC /MD/ holds 6.5556 of the shares totaling 11.01 million with a market value of $265.4 million.
Alkermes plc (ALKS) Insider Activity
The most recent transaction is an insider sale by Hopkinson Craig C., the company’s EVP R&D, Chief Medical Officer. SEC filings show that Hopkinson Craig C. sold 61,151 shares of the company’s common stock on Dec 09 ’24 at a price of $32.07 per share for a total of $1.96 million. Following the sale, the insider now owns 47576.0 shares.
Alkermes plc disclosed in a document filed with the SEC on Dec 09 ’24 that LAURENCIN CATO T (Director) sold a total of 2,691 shares of the company’s common stock. The trade occurred on Dec 09 ’24 and was made at $31.85 per share for $85708.0. Following the transaction, the insider now directly holds 23013.0 shares of the ALKS stock.
Still, SEC filings show that on Dec 09 ’24, LAURENCIN CATO T (Director) Proposed Sale 2,691 shares at an average price of $31.85 for $85708.0. The insider now directly holds shares of Alkermes plc (ALKS).
